SITE003-0051

SITE003 (CAN) › SITE003-0051

SITE003-0051

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2025-11-07

enrolled

AEs

10

Serious

0

Dropout signal

–

Adverse events

10

Grade 3 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-09-19 (study day 132); relationship: not assessed

severe assessed

Grade 1 Decreased appetite — outcome: UNKNOWN; onset 2022-08-24 (study day 106); relationship: not assessed

mild assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-08-16 (study day 98); relationship: not assessed

moderate assessed

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-08-12 (study day 94); relationship: not assessed

moderate assessed

Grade 1 Pruritus — outcome: RECOVERED/RESOLVED; onset 2022-08-10 (study day 92); relationship: not assessed

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-07-06 (study day 57); relationship: RELATED

mild assessed

Grade 2 Pruritus — outcome: RECOVERED/RESOLVED; onset 2022-06-18 (study day 39); relationship: not assessed

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-06-08 (study day 29); relationship: not assessed

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-06-02 (study day 23); relationship: not assessed

moderate assessed

Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-05-18 (study day 8); relationship: not assessed

severe assessed

Data queries

0

No data queries. Open queries would appear here for this patient.